skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Lucentis® using Visudyne® study: determining the threshold-dose fluence of verteporfin photodynamic therapy combined with intravitreal ranibizumab for exudative macular degeneration

Original Research

(1828) Views  (648) Full article downloads

Authors: Eric Chen, David M Brown, Tien P Wong, et al

Published Date September 2010 Volume 2010:4 Pages 1073 - 1079
DOI: http://dx.doi.org/10.2147/OPTH.S13969

Eric Chen, David M Brown, Tien P Wong, Matthew S Benz, Eric Kegley, Joel Cox, Richard H Fish, Rosa Y Kim
Retina Consultants of Houston, Texas, USA

Purpose: Combination verteporfin photodynamic therapy (vPDT) and antivascular endothelial growth factor (anti-VEGF) therapy may decrease the need for injections while maintaining visual acuity in exudative age-related macular degeneration. This pilot study was designed to determine the threshold fluence dose of vPDT (the dose required to demonstrate an effect on choroidal perfusion) combined with ranibizumab.
Methods: Seven patients were randomized to sham vPDT (two patients), 20% fluence vPDT (two patients), or 40% fluence vPDT (three patients) in combination with three-monthly intravitreal 0.5 mg ranibizumab injections. Intravitreal ranibizumab was reinjected if disease activity was seen on fluorescein angiography, optical coherence tomography, or clinical examination. Indocyanine green-determined choroidal hypoperfusion was graded in a masked fashion.
Results: Patients with 20% vPDT had mild hypoperfusion defects at seven days that resolved by week 4 (threshold dose); patients with 40% fluence vPDT had marked hypoperfusion at seven days that persisted as long as 12 months. Recruitment was stopped after limited efficacy was observed. One patient with 20% fluence vPDT lost 19 letters at one year; no other patient lost or gained >10 letters. Central retinal thickness decreased in six of seven patients, but ranibizumab injections did not decrease.
Conclusion: This pilot study shows that the threshold fluence dose of vPDT (when combined with ranibizumab) is approximately 20% standard fluence, and that mild and transient choroidal hypoperfusion can occur. Forty percent fluence vPDT causes a more prolonged and striking hypoperfusion. Despite hypoperfusion, no decrease in visual acuity or injections required was noted, suggesting that even higher fluence levels of vPDT may be necessary to decrease the number of anti-VEGF injections.

Keywords: neovascular age-related macular degeneration, choroidal hypoperfusion, threshold dose, verteporfin photodynamic therapy




 

Other articles by Dr Eric Chen



Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Use of nepafenac (Nevanac®) in combination with intravitreal anti-VEGF agents in the treatment of recalcitrant exudative macular degeneration requiring monthly injections
Perception of risk and benefit in patient-centered communication and care
The relationship between deliberate self-harm behavior, body dissatisfaction, and suicide in adolescents: current concepts
Zinc oxide nanoparticles as selective killers of proliferating cells
Emerging treatment options in the management of non-small cell lung cancer
Prophylactic cranial irradiation in non-small cell lung cancer patients: who might be the candidates?
Emerging nonsurgical methods for the treatment of vitreomacular adhesion: a review
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Afatinib treatment in advanced non-small cell lung cancer